Holen Sie sich die Stockscreener-App
7.83
0.25%
-0.02
Handel nachbörslich:
7.83
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com India
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian
Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat
Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat
Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com
The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therapeutics price target raised to $25 from $12 at Maxim - TipRanks
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
You might want to take a look at ACM Research Inc (ACMR) now - SETE News
When the Price of (ACRV) Talks, People Listen - Stock Traders Daily
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance
Benjamin F. Edwards & Company Inc. Has $847,000 Stock Position in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Ladenburg Thalmann Upgrades Acrivon Therapeutics Inc (ACRV) to a Buy from a Neutral - Knox Daily
Deeper Dive: Understanding Acrivon Therapeutics Inc (ACRV) Through its Various Ratios - The Dwinnex
Brighton Jones LLC Makes New Investment in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Acrivon Therapeutics Inc (ACRV) produces promising results - US Post News
Mercer Global Advisors Inc. ADV Has $2.94 Million Holdings in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
Auxier Asset Management Lowers Stake in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Purchased by Sands Capital Ventures LLC - MarketBeat
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio (NASDAQ:ACET) Rating Reiterated by Wedbush - MarketBeat
ACMR Shares Experience Surge in Value - Knox Daily
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - Defense World
Adicet Bio reports promising ADI-001 therapy data - Investing.com
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $19.80 - Defense World
Achilles gains on plans to explore strategic options - XM
Adicet Bio's (ACET) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know - Benzinga
Andrew H. Rubenstein Sells 4,114 Shares of Accel Entertainment, Inc. (NYSE:ACEL) Stock - Defense World
David W. Ruttenberg Sells 25,000 Shares of Accel Entertainment, Inc. (NYSE:ACEL) Stock - Defense World
CRISM Therapeutics Reports Positive Interim Results - TipRanks
ACM Research, Inc. (ACMR) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
ACM Research Inc (ACMR) stock: A year of ups and downs - US Post News
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches - Fierce Biotech
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Capricor secures $35 million in funding for DMD treatment By Investing.com - Investing.com Canada
Acrivon Therapeutics (NASDAQ:ACRV) Rating Reiterated by BMO Capital Markets - Defense World
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - ForexTV.com
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
Capricor Therapeutics Secures Lucrative European Partnership - TipRanks
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Yahoo Finance
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):